What is Keystone Nano?
Keystone Nano operates at the intersection of material science and clinical pharmacology, specializing in the development of nanoscale products designed to diagnose and treat human disease. The company utilizes a sophisticated platform based on calcium phosphosilicates and nanoliposomes to facilitate the precise delivery of pharmaceuticals to targeted biological sites. By offering both passive and active targeting strategies, Keystone Nano addresses significant challenges in drug solubility and therapeutic efficacy. Their business model is bifurcated into internal development programs, primarily focused on oncology, and strategic partner programs that assist pharmaceutical clients in optimizing the delivery of novel and existing chemical entities. With research facilities in State College and Hershey, Pennsylvania, the company maintains a strong intellectual property portfolio that supports its mission to improve patient outcomes through nontoxic, stable nanotechnology.
How much funding has Keystone Nano raised?
Keystone Nano has raised a total of $28K across 1 funding round:
Debt
$28K
Debt (2021): $28K with participation from PPP
Key Investors in Keystone Nano
PPP
Public-Private Partnership
National Institutes of Health
A premier public health research agency that provides critical grant funding to support innovative medical and biotechnological advancements.
Ben Franklin Partnership
A regional economic development initiative focused on fostering technological innovation and supporting early-to-growth stage companies in Pennsylvania.
What's next for Keystone Nano?
With the recent capital deployment, Keystone Nano is poised to transition from a research-heavy entity to a more commercially integrated player in the life sciences market. The strategic focus will likely center on advancing its lead candidates through rigorous clinical trials while simultaneously broadening its industrial partnerships. By refining its manufacturing processes for nanocolloids, the company aims to reduce barriers to entry for pharmaceutical partners seeking to utilize its delivery platforms. Future growth will be dictated by the firm's ability to demonstrate superior efficacy in human trials and its capacity to navigate the regulatory landscape for nano-enabled medical therapies. As the company scales, it remains a key entity to watch for potential licensing agreements and further institutional investment in the precision medicine space.
See full Keystone Nano company page
